LONDON and CAMBRIDGE, MA--(Marketwire - October 07, 2008) - Cancer drug developer Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) today announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialise novel anti-cancer compounds called PPM1D (protein phosphatase magnesium-dependent 1 d) inhibitors.